Erasca, Inc. (ERAS) Stock

Erasca, Inc. (ERAS) is a Healthcare stock trading at $13.68 (as of 2026-06-18), with a market capitalization of $3.99B and a trailing P/E of -13.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Erasca, Inc. is a clinical-stage biopharmaceutical company developing therapies for patients with cancers driven by the RAS/MAPK pathway. Its pipeline includes oral inhibitors targeting ERK1/2, SHP2, and EGFR, developed for indications such as non-small cell lung cancer, colorectal cancer, acute myeloid leukemia, advanced solid tumors, and recurrent glioblastoma multiforme.

Valuation — source: SEC EDGAR (first-party)
Price$13.68
Market Cap$3.99B
P/E Ratio-13.8
EV / EBITDA-13.6
Price / Book10.15
DCF Value (model)$-5.00
DCF Upside vs Price-136.5%
Profitability & Growth — source: SEC EDGAR
Return on Equity-70.4%
Current Ratio9.52
Valuation vs Sector & Industry
Stock P/E-13.8
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-165.9%
vs Industry-180.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFrazier Life Sciences Management, L.P. ($399.24M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJonathan E. Lim
Employees103
CountryUS
IPO Date2021-07-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Novavax, Inc. (NVAX)
  • Sana Biotechnology, Inc. (SANA)
  • Pacira BioSciences, Inc. (PCRX)
  • NovaBridge Biosciences (NBP)
  • Intellia Therapeutics, Inc. (NTLA)
  • Phibro Animal Health Corporation (PAHC)
  • Monte Rosa Therapeutics, Inc. (GLUE)
  • AbCellera Biologics Inc. (ABCL)
ERAS earnings history · ERAS institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.